TY - JOUR
T1 - Two-year outcomes among stable high-risk patients following acute MI. Insights from a global registry in 25 countries
AU - Brieger, David
AU - Pocock, Stuart J.
AU - Blankenberg, Stefan
AU - Chen, Ji Yan
AU - Cohen, Mauricio G.
AU - Granger, Christopher B.
AU - Grieve, Richard
AU - Nicolau, Jose C.
AU - Simon, Tabassome
AU - Westermann, Dirk
AU - Yasuda, Satoshi
AU - Gregson, John
AU - Rennie, Kirsten L.
AU - Hedman, Katarina
AU - Sundell, Karolina Andersson
AU - Goodman, Shaun G.
N1 - Funding Information:
D.B. Speaker/consulting honoraria and/or research grant support from AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly and Company, Merck, Novartis, Sanofi.S.B. Speaker/consulting honoraria and/or research grant support from Abbott, Abbott Diagnostics, AstraZeneca, Bayer, Boehringer Ingelheim, Medtronic, Novartis, Pfizer, Roche, Siemens, Siemens Diagnostics, Thermo Fisher Scientific.J.-Y.C. Research grant support from AstraZeneca; consulting honoraria from MicroPort, APT Medical and JW Medical.M.G.C. Speaker/consulting honoraria and/or research grant support from AstraZeneca, Medtronic, Abiomed, Merit Medical.C.B.G. Consulting honoraria and/or research grant support from Armetheon, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi Sankyo, Eli Lilly and Company, Gilead, GlaxoSmithKline, F. Hoffmann-La Roche, Janssen Pharmaceuticals, Metronic, Pfizer, Salix Pharmaceuticals, Sanofi, Takeda Pharmaceutical Company, The Medicines Company.J.C.N. Speaker/consulting honoraria and/or research grant support from Amgen, AstraZeneca, Bayer, BMS, CLS Behring, Pfizer, Sanofi.T.S. Speaker/consulting honoraria and/or research grant support from Astellas, Amgen Inc., AstraZeneca, Bayer, Boehringer Ingelheim, Eli Lilly and Company, GlaxoSmithKline, Merck, Novartis, Pfizer, Sanofi.D.W. Speaker/consulting honoraria and/or research grant support from AstraZeneca, Bayer, Berlin-Chemie, Biotronik, Novartis.S.Y. Speaker/consulting honoraria and/or research grant support from Takeda Pharmaceutical Company, Daiichi-Sankyo, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb.J.G. Grants from AstraZeneca during the conduct of the study and outside the submitted work.S.G.G. Speaker/consulting honoraria and/or research grant support from Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, CSL Behring, Daiichi Sankyo, Eli Lilly and Company, Fenix Group International, Ferring Pharmaceuticals, GlaxoSmithKline, Janssen/Johnson & Johnson, Luitpold Pharmaceuticals, Matrizyme, Merck, Novartis, Pfizer, Regeneron, Sanofi, Servier, Tenax Pharmaceuticals, HLS Therapeutics, Novo-Nordisk.The TIGRIS study and this work was supported by AstraZeneca. Being a non-interventional study, no drugs were supplied or funded. David Brieger, Stuart J. Pocock, Stefan Blankenberg, Ji Yan Chen, Mauricio G. Cohen, Christopher B. Granger, Richard Grieve, Jose C. Nicolau, Tabassome Simon, Dirk Westermann, Satoshi Yasuda, John Gregson, Kirsten L. Rennie, Katarina Hedman, Karolina Andersson Sundell, and Shaun G. Goodman conceived and designed the research; John Gregson, Katarina Hedman, Kirsten L. Rennie, and Stuart J. Pocock performed the statistical analysis; Katarina Hedman and Karolina Andersson Sundell handled funding and supervision; all coauthors acquired the data; David Brieger drafted the manuscript, and all coauthors made critical revision of the manuscript for key intellectual content. During preparation of the manuscript, editorial support was provided by Carl V. Felton, PhD, Paragon (Knutsford, Cheshire, United Kingdom), funded by AstraZeneca.
Funding Information:
The TIGRIS study and this work was supported by AstraZeneca . Being a non-interventional study, no drugs were supplied or funded. David Brieger, Stuart J. Pocock, Stefan Blankenberg, Ji Yan Chen, Mauricio G. Cohen, Christopher B. Granger, Richard Grieve, Jose C. Nicolau, Tabassome Simon, Dirk Westermann, Satoshi Yasuda, John Gregson, Kirsten L. Rennie, Katarina Hedman, Karolina Andersson Sundell, and Shaun G. Goodman conceived and designed the research; John Gregson, Katarina Hedman, Kirsten L. Rennie, and Stuart J. Pocock performed the statistical analysis; Katarina Hedman and Karolina Andersson Sundell handled funding and supervision; all coauthors acquired the data; David Brieger drafted the manuscript, and all coauthors made critical revision of the manuscript for key intellectual content. During preparation of the manuscript, editorial support was provided by Carl V. Felton, PhD, Paragon (Knutsford, Cheshire, United Kingdom), funded by AstraZeneca .
Publisher Copyright:
© 2020
PY - 2020/7/15
Y1 - 2020/7/15
N2 - Background: Evidence is lacking on long-term outcomes in unselected patients surviving the first year following myocardial infarction (MI). Methods and results: The TIGRIS (long-Term rIsk, clinical manaGement and healthcare Resource utilization of stable coronary artery dISease in post-myocardial infarction patients) prospective registry enrolled 9176 eligible patients aged ≥50 years, 1–3 years post-MI, from 25 countries. All had ≥1 risk factor: age ≥ 65 years, diabetes mellitus, second prior MI, multivessel coronary artery disease, chronic kidney disease (CKD). Primary outcome was a composite of MI, unstable angina with urgent revascularization, stroke, or all-cause death at 2-year follow-up. Bleeding requiring hospitalization was also recorded. 9027 patients (98.4%) provided follow-up data: the primary outcome occurred in 621 (7.0%), all-cause mortality in 295 (3.3%), and bleeding in 109 (1.2%) patients. Events accrued linearly over time. In multivariable analyses, qualifying risk factors were associated with increased risk of primary outcome (incidence rate ratio [RR] per 100 patient-years [95% confidence interval]): CKD 2.06 (1.66, 2.55), second prior MI 1.71 (1.38, 2.10), diabetes mellitus 1.63 (1.39, 1.92), age ≥ 65 years 1.53 (1.28, 1.83), and multivessel disease 1.24 (1.05, 1.48). Risk of bleeding events was greater in older patients (vs <65 years) 65–74 years 2.68 (1.53, 4.70), ≥75 years 4.62 (2.57, 8.28), and those with CKD 1.99 (1.18, 3.35). Conclusion: In stable patients recruited 1–3 years post-MI, recurrent cardiovascular and bleeding events accrued linearly over 2 years. Factors independently predictive of ischemic and bleeding events were identified, providing a context for deciding on treatment options.
AB - Background: Evidence is lacking on long-term outcomes in unselected patients surviving the first year following myocardial infarction (MI). Methods and results: The TIGRIS (long-Term rIsk, clinical manaGement and healthcare Resource utilization of stable coronary artery dISease in post-myocardial infarction patients) prospective registry enrolled 9176 eligible patients aged ≥50 years, 1–3 years post-MI, from 25 countries. All had ≥1 risk factor: age ≥ 65 years, diabetes mellitus, second prior MI, multivessel coronary artery disease, chronic kidney disease (CKD). Primary outcome was a composite of MI, unstable angina with urgent revascularization, stroke, or all-cause death at 2-year follow-up. Bleeding requiring hospitalization was also recorded. 9027 patients (98.4%) provided follow-up data: the primary outcome occurred in 621 (7.0%), all-cause mortality in 295 (3.3%), and bleeding in 109 (1.2%) patients. Events accrued linearly over time. In multivariable analyses, qualifying risk factors were associated with increased risk of primary outcome (incidence rate ratio [RR] per 100 patient-years [95% confidence interval]): CKD 2.06 (1.66, 2.55), second prior MI 1.71 (1.38, 2.10), diabetes mellitus 1.63 (1.39, 1.92), age ≥ 65 years 1.53 (1.28, 1.83), and multivessel disease 1.24 (1.05, 1.48). Risk of bleeding events was greater in older patients (vs <65 years) 65–74 years 2.68 (1.53, 4.70), ≥75 years 4.62 (2.57, 8.28), and those with CKD 1.99 (1.18, 3.35). Conclusion: In stable patients recruited 1–3 years post-MI, recurrent cardiovascular and bleeding events accrued linearly over 2 years. Factors independently predictive of ischemic and bleeding events were identified, providing a context for deciding on treatment options.
KW - Myocardial infarction
KW - Observational
KW - Stable coronary artery disease
UR - http://www.scopus.com/inward/record.url?scp=85079153256&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85079153256&partnerID=8YFLogxK
U2 - 10.1016/j.ijcard.2020.01.070
DO - 10.1016/j.ijcard.2020.01.070
M3 - Article
C2 - 32057476
AN - SCOPUS:85079153256
VL - 311
SP - 7
EP - 14
JO - International Journal of Cardiology
JF - International Journal of Cardiology
SN - 0167-5273
ER -